Abstract
Purpose
The objective of this study is to determine the range of SUVmax of 68Ga-DOTATATE in normal organs and tumoral lesions and establish uptake unrelated to NET.
Materials and methods
One hundred and twenty patients (57 men, 63 women), who underwent 68Ga-DOTATATE PET/CT imaging in our institution were analyzed. Patients were indicated for 68Ga-DOTATATE PET/CT imaging to detect primary tumor or metastasis of suspected or previously known NET, to determine SSTR positivity and to detect occult source of ectopic Cushing syndrome. Normal range of uptake was calculated for the organs that were proven to have no pathology by either conventional radiological imaging or clinical follow-up, using SUVmax as a semiquantitative measure. Uptake and tumor to background (T/B) ratios of tumoral lesions in liver, pancreas, bone, brain and lymph nodes were calculated. Uptakes due to lesions unrelated to NET were also documented.
Results
Significant uptake was found in spleen, kidneys, adrenal glands, liver and pituitary gland with mean SUVmax of 24.67, 14.30, 13.73, 9.12 and 9.74 respectively. Uptake was measured separately for the pancreatic head and body separately, however, besides a slightly heterogeneous uptake; the difference was not statistically significant. Uptake in the tumoral lesions had high (T/B) ratios with mean SUVmax of 28.72, 25.21, 18.28, 34.73 and 12.59 for liver, pancreas, bone, brain and lymph nodes, respectively. Incidental benign tumoral lesions were detected in 3 patients (2.5 %) which were meningioma and fibrous dysplasia demonstrating significant and breast fibroadenoma demonstrating mild 68Ga-DOTATATE uptake. Non-neoplastic processes were detected in 4 patients (14.1 %), including postsurgical inflammation, reactive lymph nodes, arthritis and demonstrated faint to mild 68Ga-DOTATATE uptake, with the exception of significant uptake in accessory spleen.
Conclusion
68Ga-DOTATATE has high T/B ratio with physiological biodistribution comparable to its counterparts. However, the presence of SSTRs in benign and malignant lesions unrelated to NET may be challenging in interpretation particularly where the physiological uptake is variable.
Similar content being viewed by others
References
Blom E, Koziorowski J. 68Ga-autoclabeling of DOTA-TATE and DOTA-NOC. Appl Radiat Isot. 2012;70:980–3.
Kendler D, Dobrozemsky G, Heute D, Uprimny C, et al. 68Ga-DOTA-Tyr3-octreotide PET in NET: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med. 2007;48:508–18.
Kowalski J, Henze M, Schuhmacher J, Macke HR, Hofmann M, Haberkorn U. Evaluation of positron emission tomography imaging using [68Ga]- DOTA-D Phe(1)-Tyr(3)-octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with NET. Mol Imaging Biol. 2003;5:42–8.
Forrer F, Valkema R, Kwekkeboom DJ, de Jong M, Krenning EP. NET. Peptide receptor radionuclide therapy. Best Pract Res Clin Endocrinol Metab. 2007;21:111–29.
Reubi JC, Schär JC, Waser B, Wenger S, Heppeler A, Schmitt JS, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000;27(3):273–82.
Kunikowska J, Królicki L, Pawlak D, Zerizer I, Mikołajczak R. Semiquantitative Analysis and Characterization of Physiological Biodistribution of 68Ga-DOTATATE PET/CT. Clin Nucl Med. 2012;37(11):1052–7.
Kuyumcu S, Adalet I, Sanli Y, Turkmen C, Ozkan ZG, Yilmazbayhan D. Somatostatin receptor scintigraphy with (111)In-octreotide in pulmonary carcinoid tumors correlated with pathological and (18)FDG PET/CT findings. Ann Nucl Med. 2012;26(9):689–97.
Buchmann I, Henze M, Engelbrecht S, Buchmann I, Henze M, Engelbrecht S, et al. Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (OctreoScan) SPECT in patients with NET. Eur J Nucl Med Mol Imaging. 2007;34:1617–26.
Kayani I, Bomanji JB, Groves A, Conway G, Gacinovic S, Win T, et al. Functional imaging of NET with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe(1), Tyr(3)-octreotate) and 18F-FDG. Cancer. 2008;112:2447–55.
Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, et al. 68Ga-DOTATyr3-octreotide PET in NET: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med. 2007;48:508–18.
Putzer D, Kroiss A, Waitz D, Gabriel M, Traub-Weidinger T, Uprimny C, et al. Somatostatin receptor PET in neuroendocrine tumors: (68)Ga-DOTA (0), Tyr (3)-octreotide versus (68)Ga-DOTA (0)-lanreotide. Eur J Nucl Med Mol Imaging. 2012. doi:10.1007/s00259-012-2286-6.
Poeppel TD, Binse I, Petersenn S, Lahner H, Schott M, Antoch G, et al. 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of NET. J Nucl Med. 2011;52(12):1864–70.
Zamora V, Cabanne A, Salanova R, Bestani C, Domenichini E, Marmissolle F, et al. Immunohistochemical expression of somatostatin receptors in digestive endocrine tumors. Dig Liver Dis. 2010;42:220–5.
Pepe G, Moncayo R, Bombardieri E, Chiti A. Somatostatin receptor SPECT. Eur J Nucl Med Mol Imaging. 2012;39(Suppl 1):S41–51.
Kaemmerer D, Peter L, Lupp A, Schulz S, Sänger J, Prasad V, et al. Molecular imaging with 68Ga-SSTR PET/CT and correlation to immunohistochemistry of somatostatin receptors in NET. Eur J Nucl Med Mol Imaging. 2011;38:1659–68.
Srirajaskanthan R, Kayani I, Quigley AM, Soh J, Caplin ME, Bomanji J. The role of 68Ga-DOTATATE PET in patients with NET and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy. J Nucl Med. 2010;51(6):875–82.
Haug AR, Cindea-Drimus R, Auernhammer CJ, Reincke M, Wängler B, Uebleis C, et al. The role of 68Ga-DOTATATE PET/CT in suspected NET. J Nucl Med. 2012;53(11):1686–92.
Kabasakal L, Demirci E, Ocak M, Decristoforo C, Araman A, Ozsoy Y, et al. Comparison of 68Ga-DOTATATE and 68Ga-DOTANOC PET/CT imaging in the same patient group with NET. Eur J Nucl Med Mol Imaging. 2012;39(8):1271–7.
Boy C, Heusner TA, Poeppel TD, Redmann-Bischofs A, Unger N, Jentzen W, et al. 68Ga-DOTATOC PET/CT and somatostatin receptor (sst1-sst5) expression in normal human tissue: correlation of sst2 mRNA and SUVmax. Eur J Nucl Med Mol Imaging. 2011;38(7):1224–36.
Shastry M, Kayani I, Wild D, Caplin M, Visvikis D, Gacinovic S, et al. Distribution pattern of 68Ga-DOTATATE in disease-free patients. Nucl Med Commun. 2010;31(12):1025–32.
Prasad V, Baum RP. Biodistribution of the Ga-68 labeled somatostatin analogue DOTA-NOC in patients with NET: characterization of uptake in normal organs and tumor lesions. Q J Nucl Med Mol Imaging. 2010;54(1):61–7.
Krausz Y, Rubinstein R, Appelbaum L, Mishani E, Orevi M, Fraenkel M, et al. Ga-68 DOTA-NOC uptake in the pancreas: pathological and physiological patterns. Clin Nucl Med. 2012;37(1):57–62.
Castellucci P, Pou Ucha J, Fuccio C, Rubello D, Ambrosini V, Montini GC, et al. Incidence of increased 68Ga-DOTANOC uptake in the pancreatic head in a large series of extrapancreatic NET patients studied with sequential PET/CT. J Nucl Med. 2011;52(6):886–90.
Hofmann M, Maecke H, Börner R, Weckesser E, Schöffski P, Oei L, et al. Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. Eur J Nucl Med. 2001;28(12):1751–7.
Schulz S, Pauli SU, Schulz S, Händel M, Dietzmann K, Firsching R, et al. Immunohistochemical determination of five somatostatin receptors in meningioma reveals frequent overexpression of somatostatin receptor subtype sst2A. Clin Cancer Res. 2000;6(5):1865–74.
Inanir S, Unlu M, Okudan B, Cila E, Atik S. Indium-111 octreotide scintigraphy in patients with bone tumours of the extremities. Eur J Nuc Med. 1996;23:987–90.
Chen CC, Czerwiec FS, Feuillan PP. Visualization of fibrous dysplasia during somatostatin receptor scintigraphy. J Nucl Med. 1998;39(2):238–40.
Conflict of interest
The authors declare no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kuyumcu, S., Özkan, Z.G., Sanli, Y. et al. Physiological and tumoral uptake of 68Ga-DOTATATE: standardized uptake values and challenges in interpretation. Ann Nucl Med 27, 538–545 (2013). https://doi.org/10.1007/s12149-013-0718-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12149-013-0718-4